PIPages
Labs

D. Moon

Tulane University of Louisiana, LA·Public Health & Epidemiology

Cervical cancer kills about 300,000 women each year, and more than 90% of those deaths happen in low- and middle-income countries. Most cases could be prevented.

Fields

Public Health & Epidemiology

Medicine & Clinical Research

Topics

cervical cancer

human papillomavirus

HPV DNA testing

Grants
1 known grant, through Aug 2029

What they work on

  1. Test implementation best practices for a Screen & Treat program that uses self-collected HPV DNA testing, delivered within HIV care and treatment services at selected health facilities in Mozambique.
  2. Measure how many screen-eligible women in routine HIV care get screened, and what share of HPV-positive women go on to receive treatment for precancerous lesions.
  3. Evaluate secondary implementation outcomes with mixed methods, combining quantitative and qualitative data, guided by the Knowledge-to-Action framework for moving evidence into clinical care.
  4. Use the trial's results to inform future research on scaling up self-sampling-based cervical cancer screening across Mozambique.

More about the research

Vaccines protect against human papillomavirus (HPV), the virus behind nearly all cervical cancers, and screening can catch precancerous changes in women already infected so they can be treated early. The World Health Organization now recommends HPV testing for screening women aged 25–49, but affordable testing is hard to get across sub-Saharan Africa, and there is little real-world experience with it there.

Why it matters

Women living with HIV in Mozambique, and in similar low-resource settings, could benefit from easier access to cervical cancer prevention. If self-collected HPV testing paired with prompt treatment works well inside HIV clinics, the findings could guide Mozambique's health system in expanding the program nationwide. That could help reduce preventable cervical cancer deaths.

Known grants

From NIH and NSF research grants. Labs often have other funding we can't see.

A hybrid type III effectiveness-implementation, pragmatic intervention trial for cervical cancer screen and treat in Mozambique

NIH · Sep 2024 – Aug 2029

Closest labs

Jean Hunleth

Washington University in St Louis, MO·Public Health & Epidemiology

Identify barriers and facilitators at multiple levels that shape HPV vaccination and primary cervical cancer prevention in rural, urban and peri-urban adolescent HIV clinics in Zambia.

John Luque

Florida Agricultural and Mechanical University, FL·Public Health & Epidemiology

Update a previously tested small-media promotora program of pamphlets and videos to improve Hispanic women's knowledge, beliefs and risk perception about cervical cancer and human papillomavirus (HPV).

Elizabeth Keating

University of Utah, UT·Medicine & Clinical Research·Early-career

Describe barriers to care for injured children at health centers and district hospitals in Tanzania, the first level of medical contact, using a mixed methods approach.

The school

Tulane University of Louisiana: 17 labs on PI Pages, $276M a year on research, 187 research doctorates a year.

More about Tulane University of Louisiana

Reach out

A start for your email. Fill in the brackets.